Other

Vegenics Limited

Vegenics Pty Limited

Ludwig Institute for Cancer Research Limited

Licentia, Ltd.

Helsinki University Licensing, Ltd.

Vegenies Limited

Vladimir Joukov

Kari Alitalo

Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides. Methods of inhibiting endothelial cell proliferation are also provided.

Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof

Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides.

[object Object]

Methods of using antibodies to VEGF-C

Vascular endothelial growth factor C (VEGF-C) protein diagnostic

Antibodies to VEGF-C

Progenitor cell materials and methods

Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof

Provided are methods of stimulating the growth of lymphatic endothelia using an Flt ligand.

Stimulation of lymphatic growth with an FLT4 ligand

Provided are polypeptide ligands for the receptor tyrosine kinase, Flt4. Also provided are cDNAs and vectors encoding the ligands, pharmaceutical compositions and diagnostic reagents comprising the ligands, and methods of making and using the ligands.

Receptor ligand VEGF-C

The invention provides antibodies that are reactive with VEGF-C, a polypeptide ligand for Flt4 receptor tyrosine kinase (VEGFR-3).

Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)

Provided are ligands for the receptor tyrosine kinase, Flt4. Also provided are cDNAs and vectors encoding the ligands, pharmaceutical compositions and diagnostic reagents.

Receptor ligand

Provided are ligands for the receptor tyrosine kinase, Flt4. Also provided are cDNAs and vectors encoding the ligand, pharmaceutical compositions and diagnostic reagents.

Growing community of inventors

Boston, MA, United States of America

Vladimir Joukov